Does Medicaid Cover Ozempic? Diabetes, Weight Loss, and State Rules

Does Medicaid cover Ozempic for diabetes?

Usually, yes. Medicaid’s drug program works through rebate agreements with drug makers. When a manufacturer is in that program, states generally must cover its drugs for medically accepted uses. KFF’s review of Medicaid coverage of GLP-1s notes that coverage of GLP-1s for diabetes is required under the rebate program.

Ozempic’s FDA label lists three uses, all for adults with type 2 diabetes:

• Improving blood sugar control, along with diet and exercise.
• Lowering the risk of heart attack, stroke, or heart-related death in people who also have heart disease.
• Lowering the risk of kidney disease getting worse, kidney failure, and heart-related death in people who also have chronic kidney disease.

“Covered” does not always mean “easy.” States manage costs through a preferred drug list, prior authorization, and step therapy. You may be asked to show a type 2 diabetes diagnosis, recent A1C results, or that you tried a lower-cost drug like metformin first. Rules differ by state and by Medicaid managed care plan.

Medicaid copays for prescriptions are small. Federal rules limit them to nominal amounts, and some groups, such as children and pregnant people, often pay nothing. Your state sets the exact copay.

Ozempic, Wegovy, and other GLP-1 drugs

A lot of confusion comes from drugs that share an ingredient but have different approved uses. Coverage depends on the drug and the reason it is prescribed.

The FDA approved Wegovy in March 2024 to reduce the risk of heart attack, stroke, and heart-related death in adults with heart disease who have obesity or overweight, as described in the FDA’s announcement. That matters for coverage, because a drug prescribed for heart risk is not being used only for weight loss.

A doctor can’t simply write “Ozempic” for weight loss to get Medicaid to pay. Pharmacy claims are checked against your diagnosis. If you don’t have type 2 diabetes, a claim for Ozempic is likely to be denied.

Weight-loss coverage is a state decision

Federal Medicaid law lists a few kinds of drugs that states may leave out of coverage. Drugs used for weight loss are one of them. California’s Medicaid agency cited this rule in its member FAQ when it ended weight-loss coverage.

That means two people with the same BMI can have different answers depending on where they live. In states that do cover weight-loss GLP-1s, coverage usually comes with conditions, such as:

• A minimum BMI, sometimes lower if you have a related health condition.
• Proof that you are in a diet and exercise program.
• Trying a preferred drug before others are approved.
• Reapproval after a set time, often tied to weight loss progress.

Children and teens are treated differently. Under the federal EPSDT benefit for members under 21, states must cover medically necessary care, so a GLP-1 may be approved case by case even where adult weight-loss coverage has ended.

State coverage we could verify

State policies have changed often since 2025, mostly because of budget pressure. We list only states where we could confirm the policy in an official or trusted source. This table was checked on November 1, 2026. Always confirm with your state Medicaid agency or plan.

North Carolina’s announcement that it would reinstitute GLP-1 coverage for weight management explains that members must try Wegovy, or have a documented reason they can’t, before Zepbound or Saxenda is approved. NC Medicaid kept covering GLP-1s for diabetes and certain heart, liver, and sleep apnea uses throughout.

KFF’s January 2026 count found 13 states covering GLP-1s for obesity in fee-for-service Medicaid, down from 16 in its October 2025 survey. KFF did not publish the full list in text, so we have not named the others. If you live in a different state, look up your state’s Medicaid preferred drug list or call member services.

The 2026 CMS BALANCE model

CMS has started a voluntary program to make GLP-1 drugs more affordable for Medicaid and, later, possibly Medicare. CMS’s BALANCE model page, last updated September 29, 2026, says:

• CMS negotiates prices with drug makers, and state Medicaid agencies can join from May 2026 through January 1, 2027.
• Drugs in the model include all forms of Ozempic, Rybelsus, Wegovy, and Mounjaro, the KwikPen form of Zepbound, and Foundayo.
• Joining is voluntary for states and manufacturers, and no one is guaranteed coverage.
• The page does not list participating states yet.

So, if your state joins, Medicaid weight-loss coverage could become available there. KFF’s explainer on the BALANCE model and Medicare Bridge says the discounted Medicaid price is confidential and the model doesn’t change Medicaid’s small copays. Watch for an announcement from your state Medicaid agency.

Medicare and dual-eligible members

If you have both Medicare and Medicaid, Medicare Part D is usually the plan that pays for your prescriptions, not Medicaid. You also qualify automatically for Extra Help, which lowers drug costs. Our guide to Medicare vs. Medicaid explains how the two programs fit together.

What Part D covers

By law, Medicare Part D can’t cover drugs used only for weight loss. It can cover GLP-1s for other FDA-approved uses, like type 2 diabetes. KFF also lists heart risk reduction and sleep apnea among uses Part D plans may cover. Each plan has its own formulary and may require prior authorization. In 2026, Medicare.gov lists a yearly cap of $2,100 on out-of-pocket costs for covered Part D drugs, as our Medicare benefits guide explains.

The Medicare GLP-1 Bridge

Separately, CMS started the Medicare GLP-1 Bridge on July 1, 2026. The CMS page says it now runs through December 31, 2027, and members pay a $50 copay for each eligible drug. Medicare.gov’s GLP-1 Bridge page lists Wegovy, Zepbound KwikPen, and Foundayo, for adults with Part D who meet BMI rules, such as a BMI of 35 or more, or lower BMIs with certain health conditions. People with type 2 diabetes aren’t eligible for the Bridge, because their Part D plan may already cover GLP-1s.

Negotiated prices coming in 2027

Ozempic, Rybelsus, and Wegovy were chosen for Medicare drug price negotiation. CMS’s negotiated prices page says the new prices take effect January 1, 2027. What you pay will still depend on your plan.

Medicare Open Enrollment runs October 15 to December 7, and as of November 1 it is open. If you take a GLP-1, use this window to check that next year’s plan still covers it and what it will cost. Medicare.gov’s help with drug costs page lists 2026 Extra Help limits of $23,940 in yearly income for one person and $32,460 for a married couple.

Getting prior authorization approved

Most denials happen because paperwork is missing. Your prescriber submits the request, but you can help it go smoothly:

1. Find your state’s criteria. Search your state Medicaid preferred drug list, or ask your managed care plan for its GLP-1 prior authorization form.
2. Make sure the diagnosis is on the request. For Ozempic, that is type 2 diabetes. For Wegovy, it may be heart disease or obesity, depending on what your state covers.
3. Bring records. Recent A1C results, a list of diabetes drugs you have tried, and your weight and BMI history help.
4. Ask about the preferred drug. If your state prefers another GLP-1, starting there can be faster.
5. Track renewal dates. Approvals often last a set number of months.

If you don’t have Medicaid yet, applying is free. Our guide on how to apply for Medicaid walks through the steps, and the main Medicaid guide covers eligibility and 2026 rule changes.

If Medicaid denies your prescription

A denial isn’t always final. Here’s what you can do:

• Read the notice. It should say why the drug was denied and how long you have to appeal.
• Ask your prescriber to resubmit with missing details, or to request an exception.
• File an appeal or ask for a fair hearing. Managed care members usually appeal to the plan first, then can ask the state for a hearing.
• Ask about other covered drugs. Another diabetes drug on your state’s list may work for you.
• Check community help. HRSA health centers offer sliding-scale care; use Find a Health Center. Local charities and churches sometimes help with prescription copays, too.

Be careful with online sellers offering cheap “semaglutide” without a prescription. Buy only from a licensed pharmacy, and talk with your doctor before switching to any compounded version.

Related guides

• Medicaid guide
• How to apply for Medicaid
• Medicare benefits guide
• Salvation Army prescription assistance

Frequently asked questions

This guide is general information, not medical or insurance advice. Drug coverage rules change often; confirm with your state Medicaid agency, your plan, or your prescriber. National Relief Program is an independent website and is not affiliated with Medicaid, Medicare, CMS, or any government agency.